Niagen Bioscience, Inc. (NAGE)
NASDAQ: NAGE · Real-Time Price · USD
6.87
-0.03 (-0.43%)
Apr 1, 2025, 4:00 PM EDT - Market closed
Niagen Bioscience Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Net Income | 8.55 | -4.94 | -16.54 | -27.13 | -19.93 | Upgrade
|
| Depreciation & Amortization | 1.48 | 1.71 | 1.88 | 1.63 | 1.51 | Upgrade
|
| Loss (Gain) From Sale of Assets | -0.02 | -0.01 | 0.01 | - | - | Upgrade
|
| Asset Writedown & Restructuring Costs | - | 0 | - | - | 0.4 | Upgrade
|
| Stock-Based Compensation | 3.66 | 4.75 | 5.74 | 6.2 | 6.94 | Upgrade
|
| Provision & Write-off of Bad Debts | -1.26 | 0.96 | 0.06 | 0.05 | 0.04 | Upgrade
|
| Other Operating Activities | -3.44 | 0.08 | 0.07 | 0.11 | 0.09 | Upgrade
|
| Change in Accounts Receivable | -1.28 | 2.26 | -3.32 | -2.58 | -0.56 | Upgrade
|
| Change in Inventory | 5.33 | 0.15 | -1.08 | -1.92 | -0.15 | Upgrade
|
| Change in Accounts Payable | -1.07 | 0.55 | -0.74 | 0.98 | -0.18 | Upgrade
|
| Change in Unearned Revenue | -0.32 | -0.61 | -0.4 | -0.21 | 0.67 | Upgrade
|
| Change in Other Net Operating Assets | 0.46 | 2.21 | -0.78 | -1.28 | 0.56 | Upgrade
|
| Operating Cash Flow | 12.11 | 7.12 | -15.1 | -24.16 | -10.6 | Upgrade
|
| Operating Cash Flow Growth | 70.14% | - | - | - | - | Upgrade
|
| Capital Expenditures | -0.16 | -0.15 | -0.33 | -0.41 | -0.12 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.02 | 0.01 | - | - | - | Upgrade
|
| Sale (Purchase) of Intangibles | - | - | - | - | -0.02 | Upgrade
|
| Other Investing Activities | - | - | - | - | -0.02 | Upgrade
|
| Investing Cash Flow | -0.14 | -0.14 | -0.33 | -0.41 | -0.17 | Upgrade
|
| Long-Term Debt Repaid | -0.01 | -0.02 | -0.02 | -0.03 | -0.27 | Upgrade
|
| Net Debt Issued (Repaid) | -0.01 | -0.02 | -0.02 | -0.03 | -0.27 | Upgrade
|
| Issuance of Common Stock | 5.43 | - | 7.75 | 36.24 | 8.97 | Upgrade
|
| Other Financing Activities | -0.05 | -0.08 | -0.08 | -0.11 | -0.05 | Upgrade
|
| Financing Cash Flow | 5.37 | -0.09 | 7.65 | 36.09 | 8.65 | Upgrade
|
| Net Cash Flow | 17.34 | 6.88 | -7.78 | 11.52 | -2.12 | Upgrade
|
| Free Cash Flow | 11.95 | 6.97 | -15.43 | -24.57 | -10.72 | Upgrade
|
| Free Cash Flow Growth | 71.42% | - | - | - | - | Upgrade
|
| Free Cash Flow Margin | 11.99% | 8.34% | -21.42% | -36.43% | -18.10% | Upgrade
|
| Free Cash Flow Per Share | 0.15 | 0.09 | -0.22 | -0.37 | -0.18 | Upgrade
|
| Cash Interest Paid | 0 | 0 | 0 | 0 | 0.01 | Upgrade
|
| Levered Free Cash Flow | 9.61 | 9.47 | -9.64 | -13.5 | -3.32 | Upgrade
|
| Unlevered Free Cash Flow | 9.61 | 9.47 | -9.64 | -13.46 | -3.27 | Upgrade
|
| Change in Net Working Capital | 0.2 | -6.66 | 5.28 | 3.96 | -0.83 | Upgrade
|
Updated Mar 4, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.